Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis

Patrick H. Nachman, Elizabeth S. Kotzen, Susan L. Hogan, JulieAnne G. McGregor, Donna O. Bunch, Jason M. Kidd, Ronald J. Falk, Caroline J. Poulton, Suzanne L. Katsanos, Roberto Negrete-Lopez, Yichun Hu
2015
Rituximab has been used in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) since 2003. Our objective was to describe outcomes and adverse events following rituximab since that time in an inception cohort.
doi:10.17615/th89-3a59 fatcat:gmzoyosq4ffszmndqhtxve5tue